Tubulis is a Munich-based life science start-up dedicated to the research and development of antibody drug conjugates (ADCs). Driven by a team of passionate founders, the company is experiencing remarkable growth and establishing a strong foundation for groundbreaking drug treatments
Recognizing the significance of cultivating a professional and distinctive brand identity, the Tubulis team sought our expertise to craft an identity that would authentically represent their work and distinguish them within their competitive landscape. Delving deep into the intricacies of Tubulis‘ scientific endeavors, we conceptualized a logo and identity that artfully mirrors their primary area of research. Much like the way their drug conjugates bind to antibodies, our identity system features a „magnetic“ logo and content boxes. Coupled with a vibrant color palette, a set of unique icons, and a prominent antibody visual, the Tubulis identity seamlessly embodies the zeal of its youthful founders and the intricacies of their scientific pursuits.
For Tubulis, their company’s identity transcends mere aesthetics; it encapsulates their mission, passion, and unwavering determination to contribute to a better world through research and innovation. It is an integral part of their essence.
Since its inception, Tubulis has achieved significant milestones, most recently securing a $1 billion strategic license agreement with Bristol Myers Squibb to develop differentiated antibody-drug conjugates (ADCs). Learn more about their journey here.
„Tubulis raised over 60 million euros in capital in 2022. In addition to a relevant technology, the bold brand development, away from the norms, as an expression of a future brand, was a major confidence factor for investors.“
– Philippe Henco, Managing Partner Strategy KittoKatsu